Catenin beta-1:Transcription factor 7-like 2 interaction (β-catenin:TCF4 interaction)

The Catenin beta-1:Transcription factor 7-like 2 (β-catenin:TCF4) interaction is a fundamental regulatory node in the canonical Wnt signaling pathway, responsible for the transcriptional activation of genes governing cell fate, proliferation, and survival [6, 11]. In the presence of Wnt ligands, β-catenin escapes degradation, accumulates in the cytoplasm, and translocates to the nucleus where it binds to TCF4 (TCF7L2) to form a functional transcription factor complex [2, 12]. This interaction is frequently hyperactivated in human cancers, particularly colorectal cancer, due to mutations in APC or β-catenin itself that lead to constitutive gene expression of oncogenic targets like c-Myc and Cyclin D1 [5, 14]. As a therapeutic target, the β-catenin:TCF4 interface is characterized by a large, relatively flat protein-protein interaction surface, making it historically difficult to target with small molecules [1, 13]. Modern drug discovery efforts have produced selective inhibitors, such as the stapled peptide FOG-001 and small molecules like LF3, which aim to disrupt this specific interaction while sparing the essential role of β-catenin in E-cadherin-mediated cell adhesion [10, 13, 15]. Successful therapeutic intervention requires high selectivity to avoid systemic toxicities associated with the inhibition of physiological Wnt signaling in healthy regenerative tissues like the intestinal epithelium and bone marrow [1, 13].

Other names

CTNNB1:TCF7L2 interactionβ-catenin/TCF4 transcriptional complexWnt/β-catenin signaling complexβ-catenin/TCF4 PPICatenin beta-1:T-cell factor 4 interaction

Competitive inhibition of the protein-protein interaction (PPI) between the armadillo repeat domain of Catenin beta-1 (β-catenin) and the N-terminal binding domain of Transcription factor 7-like 2 (TCF4/TCF7L2) [1, 9, 10]. By disrupting this interaction, drugs prevent the formation of the active nuclear transcriptional complex, thereby blocking the recruitment of co-activators and the subsequent expression of Wnt-responsive oncogenes such as MYC and CCND1 [2, 6, 12].